Beta Amyloid News and Research

RSS

BACE2 enzyme could represent powerful new tool against Alzheimer's

An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme - known as BACE2 - destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease.

18 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

University of Rhode Island engineers develop new blood-testing technology

A team of engineers and students at the University of Rhode Island has developed an advanced blood-testing technology that incorporates a smartphone application, a hand-held biosensor and a credit card-sized cartridge to provide rapid, accurate biological analysis and wireless communication of test results.

7 Sep 2012

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

Eli Lilly and Company today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease.

24 Aug 2012

Scientists take step toward developing blood test for Alzheimer's

The possibility of an inexpensive, convenient test for Alzheimer's disease has been on the horizon for several years, but previous research leads have been hard to duplicate.

12 Aug 2012

Advanced Radiology to offer Amyvid for detection of AD

Advanced Radiology, a division of RadNet, Inc., a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 237 fully-owned and operated outpatient imaging centers, announced it will be one of a small number of imaging centers in the U.S. to offer Amyvid, a radioactive tracer used in positron emission tomography – computed tomography (PET/CT) imaging that helps to detect the quantity of beta-amyloid plaque in patient's brains.

8 Aug 2012

Diacetyl intensifies damaging effects of beta-amyloid proteins linked to Alzheimer's

A new study raises concern about chronic exposure of workers in industry to a food flavoring ingredient used to produce the distinctive buttery flavor and aroma of microwave popcorn, margarines, snack foods, candy, baked goods, pet foods and other products.

2 Aug 2012

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.

24 Jul 2012

GE Healthcare announces final results from [18F]flutemetamol phase 3 study on AD

GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.

18 Jul 2012

New Alzheimer's model derived from skin cells of patients may prove to be more accurate

Researchers at the Alzheimer's Association International Conference 2012 (AAIC 2012) today reported the creation of a new model of Alzheimer's derived from the skin cells of people with the disease that were reprogramed into Alzheimer's brain cells.

17 Jul 2012

Scientists develop first cell-based model of Alzheimer's disease

A team of scientists at The New York Stem Cell Foundation (NYSCF) Laboratory led by Scott Noggle, PhD, NYSCF-Charles Evans Senior Research Fellow for Alzheimer's Disease, has developed the first cell-based model of Alzheimer's disease (AD) by reprogramming skin cells of Alzheimer's patients to become brain cells that are affected in Alzheimer's.

17 Jul 2012

James J. Peters Veterans Hospital actively enrolls participants for NIC5-15 phase IIb trial in AD

The James J. Peters Veterans Hospital in Bronx, New York, is actively recruiting participants for a phase IIb clinical trial testing NIC5-15, a disease modifying candidate for Alzheimer's disease.

14 Jul 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012

GMCSF linked with rapid cognitive recovery in patients with cancer

Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.

23 Jun 2012

First study to link risk of cognitive decline to severity of diabetes

Preventing diabetes or delaying its onset has been thought to stave off cognitive decline -- a connection strongly supported by the results of a 9-year study led by researchers at the University of California, San Francisco (UCSF) and the San Francisco VA Medical Center.

23 Jun 2012